Guitton et al[6] (2018), in a multi-center retrospective cohort study including 18 patients with SLE-ITP treated with TPO-R agonists, 55% (10 patients) had APLA and 27% (5 patients) had definite APS. The gene discussed is MPL; the disease is autoimmune polyendocrinopathy.